15,618 Shares in LeMaitre Vascular, Inc. $LMAT Bought by Caitlin John LLC

Key Points

• Caitlin John LLC has invested approximately $1.30 million in LeMaitre Vascular, acquiring 15,618 shares, which now represent 1.2% of its portfolio.
• Several analysts have upgraded the stock, with a **target price increase** to $95.00 from previous estimates, while maintaining a consensus target price of $97.60.
• Insider transactions have shown significant selling, with directors reducing their holdings by over 40%, which totaled about $11.3 million in stock sold last quarter.

Caitlin John LLC purchased a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,618 shares of the medical instruments supplier's stock, valued at approximately $1,297,000. LeMaitre Vascular makes up approximately 1.2% of Caitlin John LLC's holdings, making the stock its 29th largest holding. Caitlin John LLC owned about 0.07% of LeMaitre Vascular at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Opal Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular in the first quarter worth $26,000. NBC Securities Inc. acquired a new stake in LeMaitre Vascular in the first quarter worth about $36,000. Geneos Wealth Management Inc. lifted its holdings in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 398 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in LeMaitre Vascular in the first quarter worth about $50,000. Finally, US Bancorp DE raised its position in LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after acquiring an additional 368 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LMAT shares. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research report on Wednesday, August 6th. Cantor Fitzgerald boosted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular currently has a consensus rating of "Hold" and an average target price of $97.60.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 10,815 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the sale, the director directly owned 17,976 shares of the company's stock, valued at approximately $1,660,802.64. This represents a 37.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the sale, the director directly owned 2,916 shares in the company, valued at approximately $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,815 shares of company stock valued at $11,280,206. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of LMAT stock traded up $0.04 during trading on Monday, reaching $92.29. 171,259 shares of the company's stock were exchanged, compared to its average volume of 183,602. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The firm's fifty day moving average price is $90.69 and its 200-day moving average price is $86.05. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.09 billion, a PE ratio of 44.80, a PEG ratio of 2.37 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. During the same quarter in the prior year, the business earned $0.52 EPS. The firm's revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is currently 38.83%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.